Regression from prediabetes to normal glucose regulation: State of the science
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Prediabetes, an intermediate stage between normal glucose regulation and type 2 diabetes, is diagnosed based on documentation of impaired fasting glucose, impaired glucose tolerance, or a hemoglobin A1c level of 5.7–6.4%. Individuals with prediabetes have increased risks for the development of type 2 diabetes and multiple vascular complications. Randomized controlled trials have demonstrated the feasibility of preventing progression from prediabetes to type 2 diabetes, using lifestyle or pharmacological interventions. Lifestyle modification has a sustained effect on diabetes prevention, whereas medications lose efficacy when discontinued. Few studies have pre-specified reversal of prediabetes as the primary outcome. There is emerging evidence that reversal of prediabetes (i.e. restoration of normal glucose regulation) confers significant protection from future diabetes and complications, including premature death, during long-term follow-up. Current lifestyle intervention protocols have been more effective in preventing progression from prediabetes to type 2 diabetes than restoring normal glucose regulation; thus, interventions that prevent type 2 diabetes in people with prediabetes do not always reverse prediabetes. Given the compelling benefits of restoration of normal glucose regulation, specific protocols for reversal of prediabetes need to be developed and tested. The design of such protocols requires a deeper understanding of the pathobiology of prediabetes and early glucose dysregulation. The present review focuses on those studies that have assessed the impact of interventions on regression of the prediabetes state and restoration of normal glucose regulation. Furthermore, we discuss alterations in adiposity, glucoregulatory mechanisms, metabolomics, inflammatory markers, and other factors that predict the initial escape from normoglycemia. Such knowledge could inform the future development of novel, refined, and targeted interventions for the reversal prediabetes/early dysglycemia and restoration of normal glucose regulation. Impact statement: Prediabetes increases the risks of future type 2 diabetes (T2D) and vascular complications, risks that can be prevented by restoring normal glucose regulation (NGR). Few studies have pre-specified reversal of prediabetes and restoration of NGR as primary outcome, and current approaches that prevent T2D in people with prediabetes do not always reverse the prediabetes. The present review focuses on studies that have assessed reversal of the prediabetes, and discusses known and emerging predictors of prediabetes. We argue that fuller knowledge of such predictors could inform the discovery of novel, targeted interventions for reversing prediabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 3×
“The participants were randomized to three treatment groups: standard lifestyle recommendations plus metformin group; standard lifestyle recommendations plus placebo group; and an intensive lifestyle modification group (low calorie, low-fat diet, and at least 150min per week of moderate intensity physical activity with…”
BackgroundMethodResultTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The results of other RCTs, including the Finnish Diabetes Prevention Study, the Indian Diabetes Prevention Program (IDPP)-1 and IDPP-2, showed significant reduction in the risk of progression from prediabetes to T2D following lifestyle intervention.(15,16,21) The IDPP-1 tested the effects of a control intervention (st…”
ResultInfluentialLifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164 · cited 4×
“Schauer et al.(39) randomized 150 patients with T2D (age 49 8 years; BMI 37; HbA1c 9.”
BackgroundResultInfluentialWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 6×
“The term “prediabetes” has been used in the medical literature since 1918.50 The modern definition of prediabetes, based on precise blood glucose measurement, includes individuals with IFG and/or IGT.”
BackgroundInfluentialXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 2×
“The XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study randomized 3305 obese patients to lifestyle modification plus either orlistat 120mg or placebo, three times daily and followed them for four years.(27) The participants had normal (79%) or impaired (21%) glucose tolerance at enrollment.”
BackgroundMethodGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 1×
“However, the amount of weight loss ( 5–7%) required for diabetes prevention in people with prediabetes is achievable by non-surgical means, and prediabetes, per se, is currently not one of the indications for bariatric surgery in professional guidelines.(44,45)”
Background
Cited by
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P. H., Wallenstein, S. O. R., & le Roux, C. W. (2022) · Diabetes Care · doi:10.2337/dc21-1785 · Cited by 87
“studies report reversion rates of 31–52% with lifestyle intervention only, 20% with metformin, 35% with acarbose, 50% with rosiglitazone or pioglitazone, and 66% with liraglutide (23,24).”
BackgroundHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Self-citationRuseva, A., Michalak, W., Zhao, Z., Fabricatore, A., Hartaigh, B. Ó., & Umashanker, D. (2024) · Obesity Science & Practice · doi:10.1002/osp4.737 · Cited by 40
“30,31 It is important to note that while direct comparison of the effect sizes of these studies was not feasible due to disparities in factors such as patient attributes, study configuration, and various follow ‐ up durations, the robustness of the impact of semaglutide on glycemic status remained…”
BackgroundDobbie, L. J., Coelho, C., Mgaieth, F., Chauhan, K., Campbell, S., Shuriye, S., Hollington, J., Appleton, S., Sen Gupta, P., Duncan, A., et al. (2024) · Clinical Obesity · doi:10.1111/cob.12649 · Cited by 12
Metadata
- Authors
- Sallar, A., & Dagogo-Jack, S.
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 2020-03-25
- Volume
- 245
- Issue
- 10
- Pages
- 889-896
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W3013366238
- Cited by
- 63
- References
- 27
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regression from prediabetes to normal glucose regulation: State of the science. https://app.cochat.ai/papers/10.1177/1535370220915644
- The paper
- Sallar, A., & Dagogo-Jack, S. (2020). Regression from prediabetes to normal glucose regulation: State of the science. Experimental Biology and Medicine. https://doi.org/10.1177/1535370220915644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.